Announcement on New Cumulative Litigation and Arbitration Cases
The company and its board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.
Chongqing Pharmaceutical Holding Co., Ltd. (hereinafter referred to as the "Company") has, in accordance with the "Shenzhen Stock Exchange Stock Listing Rules," compiled statistics on litigation and arbitration matters involving the Company and its holding subsidiaries within a continuous twelve-month period. The relevant statistical information is hereby announced as follows:
I. Basic Situation of New Cumulative Litigation and Arbitration Cases
As of the disclosure date of this announcement, excluding previously disclosed litigation and arbitration matters, the total amount involved in new, undisclosed litigation and arbitration matters by the Company and its holding subsidiaries within a continuous twelve-month period is RMB 128,878.07 million. The cumulative amount involved accounts for 11.17% of the company's net assets attributable to the parent company as of the most recent audited period. Among these, the amount involved in cases where the Company and its holding subsidiaries are the plaintiffs totals RMB 119,329.62 million.
There are no major litigation or arbitration cases where the amount involved individually exceeds RMB 10 million and the absolute value accounts for more than 10% of the company's net assets as of the most recent audited period. For specific details, please refer to the "Statistical Table of Cumulative Litigation and Arbitration Cases Not Disclosed Within Twelve Months."
II. Other Undisclosed Litigation and Arbitration Cases
There are no other litigation or arbitration cases that should be disclosed but have not been disclosed by the Company and its holding subsidiaries.
III. Possible Impact of the Litigation and Arbitration Announced This Time on the Company's Current and Future Profits
Given that some cases have not yet been heard or concluded, the impact on the Company's current or future profits is uncertain. The Company will make corresponding accounting treatments in accordance with the requirements of accounting standards and the actual situation of the cases, and will fulfill its information disclosure obligations in a timely manner as required by the "Shenzhen Stock Exchange Stock Listing Rules."
At the same time, the Company will continue to pay attention to the subsequent progress of relevant litigation and arbitration cases, actively take relevant measures to protect the legitimate rights and interests of the Company and its holding subsidiaries, and fulfill its information disclosure obligations in a timely manner as required by the "Shenzhen Stock Exchange Stock Listing Rules." We kindly remind investors to be aware of investment risks.
IV. Documents for Inspection
- Legal documents such as summons, notices of case acceptance, and judgments.
Attachment: Statistical Table of Cumulative Litigation and Arbitration Cases Not Disclosed Within Twelve Months
Hereby announced,
Board of Directors of Chongqing Pharmaceutical Holding Co., Ltd.
August 5, 2026